KLRA — what changed in the latest 10-Q
A section-by-section comparison of KLRA's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-12 vs the prior 10-Q · 2026-05-26
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +28 | −15 | ~14 | 50 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 3 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Risk factors | Text added/removed | +1 | 0 | ~11 | 581 |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-12
In July 2026, Hengrui reported positive topline data from its Phase 3 trial of once-weekly ribupatide injection (4 mg and 2 mg) in type 2 diabetes, or T2D, patients with inadequate glycemic control despite diet and exercise interventions in China. Ribupatide injection showed significant reductions i…
In July 2026, Hengrui reported positive topline data from two Phase 3 clinical trials of KAI-7535 (being developed by Hengrui in Greater China as HRS-7535). In Hengrui’s Phase 3 trial in adults with obesity in China, participants taking HRS-7535 180 mg achieved a mean weight loss of up to 11.1% from…
Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss wa…
deficit of $558.8 million. We expect to continue to incur significant expenses and recognize operating losses for at least the next several years as we advance our product candidates through later stage clinical development and seek regulatory approval of our product candidates. In addition, if we o…
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our operations with proceeds from outside sources, wi…
Text removed vs the prior filing · source: 10-Q · 2026-05-26
In May 2026, we and Hengrui reported positive topline data from Hengrui’s Phase 3 type 2 diabetes, or T2D, clinical trial of KAI-7535 (being developed by Hengrui in Greater China as HRS-7535). In the first of multiple Phase 3 trials, HRS-7535 met the primary endpoint by demonstrating a significant h…
In May 2026, we and Hengrui reported positive topline data from Hengrui’s Phase 1 single ascending and multiple ascending dose trial of KAI-4729 (being developed by Hengrui in Greater China as HRS-4729). HRS-4729 demonstrated safety and tolerabilty data consistent with GLP-1-based treatments. In a s…
Since our inception, we have incurred significant operating losses. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. Our net loss wa…
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations with proceeds from outside sources, with a majority of…
as to manage our nonclinical, clinical and manufacturing development activities. These employees work across multiple product candidates and, therefore, we do not track these costs by product candidate.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-12
could put our patent rights at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation and proceedings, there is a risk that some of our confidential information co…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice